Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) saw a significant increase in short interest by 49.4% in January, reaching 585,301 shares, representing 1.8% of outstanding shares and a 2.8 days-to-cover ratio. Despite low institutional ownership at 0.53%, several investors have recently added or initiated positions. Analysts maintain a “Moderate Buy” consensus with an average target price of $179.75 for the stock, which has a market cap of $6.57 billion.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) saw a significant increase in short interest by 49.4% in January, reaching 585,301 shares, representing 1.8% of outstanding shares and a 2.8 days-to-cover ratio. Despite low institutional ownership at 0.53%, several investors have recently added or initiated positions. Analysts maintain a “Moderate Buy” consensus with an average target price of $179.75 for the stock, which has a market cap of $6.57 billion.